PolyPid Ltd (NAS:PYPD)

Q3 2024 PolyPid Ltd Earnings Call Transcript

Nov 13, 2024 / 01:30 PM GMT

Release Date Price: $3.4 (-2.86%)

Transcript

Key Points

Positve

PolyPid Ltd (PYPD) has achieved significant acceleration in patient enrollment for the Shield 2 pivotal trial, with approximately 550 subjects enrolled and 60 centers open globally.
The company is operating from a position of financial strength, with funding secured beyond the upcoming interim analysis and into 2026 if all warrants are exercised.
The Shield 1 trial results, which showed highly positive and statistically significant data, were published in the prestigious International Journal of Surgery.
PolyPid Ltd (PYPD) has the potential to secure an additional $24.6 million through warrant exercises from recent private placement financings, extending their cash runway.
The company has ongoing discussions with strategic partners for the commercialization of DPLEX 100 in the US and other regions, indicating strong interest in the product's market potential.

Negative

PolyPid Ltd (PYPD) reported a net loss of $7.8 million for the third quarter of 2024, an increase from $5.6 million in the same period of 2023.
Research and development expenses increased significantly to $6 million, up from $3.8 million in the previous year, driven by the ramp-up in patient enrollment.
The company’s current cash balance is expected to fund operations only into the first quarter of 2025, highlighting a need for additional funding.
There is uncertainty regarding the outcome of the Shield 2 trial's interim analysis, which could impact the trial's continuation or early conclusion.
PolyPid Ltd (PYPD) faces risks associated with the potential for futility in the Shield 2 trial, although management expresses confidence in the trial's success.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PYPD.OQ - PolyPid Ltd
Q3 2024 PolyPid Ltd Earnings Call
Nov 13, 2024 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you all for participating in Pope's third quarter, 2024 earnings conference call. Joining me on the call today will be Dikla Chaus Axelrad, Chief Executive Officer of Poly Pede Johnny Misal allowing Poly Pe's Chief Financial Officer and Ori Ropy Chief Operating Officer US of Poly P. Earlier today, Poly P released its financial results for the three and nine months ended. September 30th 2024. A copy of the press release is available in the investors section on the company's website www dot poly dotcom.

I'd like to remind you that on this call. Management will make forward-looking statements within the meaning of the federal securities laws. For example, management is making forward-looking statements when it discusses the potential

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.